Management of side effects of androgen deprivation therapy

Grossmann, Mathis; Zajac, Jeffrey D.

doi:10.1016/j.ecl.2011.05.004

Cited by 69Prostate Cancer Treatment and ResearchHormonal and reproductive studiesProstate Cancer Diagnosis and Treatment

Management of side effects of androgen deprivation therapy

Grossmann, Mathis, Zajac, Jeffrey D.·2011·Endocrinology and Metabolism Clinics of North America

DOI 10.1016/j.ecl.2011.05.004

Open this paper in CoChat — free account

Abstract

Androgen deprivation therapy (ADT) is a major component of the contemporary management of prostate cancer. ADT's use is increasing rapidly. The side effects of this therapy include loss of bone mass and fractures, increase in fat mass, and worsening of insulin resistance, the metabolic syndrome, diabetes and cardiovascular risk, and anemia and loss of muscle. Neuropsychological and sexual symptoms are common. The impact of these side effects is often overlooked or underestimated in decisions about prostate cancer therapy. This review surveys the data relating to the side effects of ADT and provides recommendations regarding their minimization and management.

Integrity signals

Registry

Crossref · 10.1016/j.ecl.2011.05.004

Cites

98 of 98 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Men with prostate cancer receiving androgen deprivation therapy develop very low testosterone and severely symptomatic androgen deficiency with osteo-sarcopenic obesity and increased insulin resistance.
“In contrast to men with functional hypogonadism who have only modestly low testosterone levels, men with prostate cancer receiving androgen deprivation therapy develop very low testosterone and severely symptomatic androgen deficiency with osteo-sarcopenic obesity and increased insulin resistance (14).”
From A Perspective on Middle-Aged and Older Men With Functional Hypogonadism: Focus on Holistic Management (2017) · cites this paper as [14]

Mortality after all major types of osteoporotic fracture in men and women: an observational study
Nguyen, T. V., Schneider, D. L., Sambrook, P. N., & Eisman, J. A. (1999) · The Lancet · doi:10.1016/s0140-6736(98)09075-8 · Cited by 1,926 · see citing works
Hyperinsulinemia as an independent risk factor for ischemic heart disease
Després, J.-P., Lamarche, B., Mauriège, P., Cantin, B., Dagenais, G. R., Moorjani, S., & Lupien, P.-J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604113341504 · Cited by 1,699 · see citing works
Adverse Events Associated with Testosterone Administration
Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000485 · Cited by 1,494 · see citing works
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Keating, N. L., O'Malley, A. J., & Smith, M. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2497 · Cited by 1,455 · see citing works
Risk of Fracture after Androgen Deprivation for Prostate Cancer
Shahinian, V. B., Kuo, Y., Freeman, J. L., & Goodwin, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041943 · Cited by 1,375 · see citing works
Glucose Transporters and Insulin Action — Implications for Insulin Resistance and Diabetes Mellitus
Shepherd, P. R., & Kahn, B. B. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907223410406 · Cited by 1,295 · see citing works
Denosumab in men receiving androgen-deprivation therapy for prostate cancer
Smith, M. R., Egerdie, B., Toriz, N. H., Feldman, R., Tammela, T. L. J., Saad, F., Heracek, J., Szwedowski, M., Ke, C., Kupic, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809003 · Cited by 1,140 · see citing works
Androgen Deprivation Therapy for Prostate Cancer
Sharifi, N. (2005) · JAMA · doi:10.1001/jama.294.2.238 · Cited by 1,087 · see citing works
Duration of Androgen Suppression in the Treatment of Prostate Cancer
Bolla, M., de Reijke, T. M., van Tienhoven, G., van den Bergh, A. C. M., Oddens, J. R., Poortmans, P. M., Gez, E., Kil, P. J. M., Akdaş, A., Soete, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810095 · Cited by 970 · see citing works
Osteoporosis in Men
Khosla, S., Amin, S., & ORWOLL, E. S. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0002 · Cited by 934 · see citing works
Resistance Exercise in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
SEGAL, R. J., Reid, R. D., Courneya, K. S., Malone, S. C., Parliament, M. B., Scott, C. G., Venner, P. M., Quinney, H. A., Jones, L. W., D’Angelo, M. E. S., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.534 · Cited by 786 · see citing works
Changes in body composition during androgen deprivation therapy for prostate cancer
Smith, M. R., Finkelstein, J. S., McGovern, F. J., Zietman, A. L., Fallon, M. A., Schoenfeld, D. A., & Kantoff, P. W. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8299 · Cited by 697 · see citing works
Pamidronate to Prevent Bone Loss during Androgen-Deprivation Therapy for Prostate Cancer
Smith, M. R., McGovern, F. J., Zietman, A. L., Fallon, M. A., Hayden, D. L., Schoenfeld, D., Kantoff, P. W., & Finkelstein, J. S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010845 · Cited by 695 · see citing works
Androgen Suppression and Radiation vs Radiation Alone for Prostate Cancer
D'Amico, A. V., Chen, M., Renshaw, A. A., Loffredo, M. J., & Kantoff, P. W. (2008) · JAMA · doi:10.1001/jama.299.3.289 · Cited by 692 · see citing works
Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006
Cowie, C. C., Rust, K. F., Byrd-Holt, D. D., Gregg, E. W., Ford, E. S., Geiss, L. S., Bainbridge, K. E., & Fradkin, J. E. (2010) · Diabetes Care · doi:10.2337/dc09-1524 · Cited by 689 · see citing works
Combined Resistance and Aerobic Exercise Program Reverses Muscle Loss in Men Undergoing Androgen Suppression Therapy for Prostate Cancer Without Bone Metastases: A Randomized Controlled Trial
Galvão, D. A., Taaffe, D. R., Spry, N., Joseph, D., & Newton, R. U. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2488 · Cited by 657 · see citing works
Randomized Controlled Trial of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer
Smith, M. R., Eastham, J. A., Gleason, D. M., Shasha, D., Tchekmedyian, S., & Zinner, N. R. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000063820.94994.95 · Cited by 650 · see citing works
Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy: Observational Study of Veterans With Prostate Cancer
Keating, N. L., O'Malley, A. J., Freedland, S. J., & Smith, M. R. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp404 · Cited by 622 · see citing works
Leuprolide versus Diethylstilbestrol for Metastatic Prostate Cancer
The Leuprolide Study Group (1984) · New England Journal of Medicine · doi:10.1056/nejm198411153112004 · Cited by 622 · see citing works
Epidemiology of prostate cancer
Crawford, E. D. (2003) · Urology · doi:10.1016/j.urology.2003.10.013 · Cited by 543 · see citing works
Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer
Saigal, C. S., Gore, J. L., Krupski, T. L., Hanley, J., Schonlau, M., & Litwin, M. S. (2007) · Cancer · doi:10.1002/cncr.22933 · Cited by 542 · see citing works
Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions
D'Amico, A. V., Denham, J. W., Crook, J., Chen, M.-H., Goldhaber, S. Z., Lamb, D. S., Joseph, D., Tai, K.-H., Malone, S., Ludgate, C., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.3369 · Cited by 501 · see citing works
Megestrol acetate for the prevention of hot flashes.
Loprinzi, C. L., Michalak, J. C., Quella, S. K., O'Fallon, J. R., Hatfield, A. K., Nelimark, R. A., Dose, A. M., Fischer, T., Johnson, C., Klatt, N. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199408113310602 · Cited by 500 · see citing works
Insulin sensitivity during combined androgen blockade for prostate cancer
Smith, M. R., Lee, H., & Nathan, D. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2507 · Cited by 493 · see citing works
Low testosterone levels are common and associated with insulin resistance in men with diabetes
Grossmann, M., Thomas, M. C., Panagiotopoulos, S., Sharpe, K., MacIsaac, R. J., Clarke, S., Zajac, J. D., & Jerums, G. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2177 · Cited by 468 · see citing works
Self-citation
The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer
Smith, J. C., Bennett, S., Evans, L. M., Kynaston, H. G., Parmar, M., Mason, M. D., Cockcroft, J. R., Scanlon, M. F., & Davies, J. S. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.9.7851 · Cited by 458 · see citing works
Prostate cancer
Damber, J., & Aus, G. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60729-1 · Cited by 418 · see citing works
Bone Loss after Initiation of Androgen Deprivation Therapy in Patients with Prostate Cancer
Greenspan, S. L., Coates, P. S., Sereika, S. M., Nelson, J. B., Trump, D. L., & Resnick, N. M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0183 · Cited by 412 · see citing works
Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk: A Science Advisory From the American Heart Association, American Cancer Society, and American Urological Association: <i>Endorsed by the American Society for Radiation Oncology</i>
Levine, G. N., D'Amico, A. V., Berger, P., Clark, P. E., Eckel, R. H., Keating, N. L., Milani, R. V., Sagalowsky, A. I., Smith, M. R., & Zakai, N. (2010) · Circulation · doi:10.1161/circulationaha.109.192695 · Cited by 383 · see citing works
Calcium and fructose intake in relation to risk of prostate cancer.
Giovannucci, E. L., Rimm, E. B., Wolk, A., Ascherio, A., Stampfer, M. J., Colditz, G. A., & Willett, W. C. (1998) · PubMed · Cited by 367 · see citing works
Gonadotropin-Releasing Hormone Agonists and Fracture Risk: A Claims-Based Cohort Study of Men With Nonmetastatic Prostate Cancer
Smith, M. R., Lee, W. C., Brandman, J., Wang, Q., Botteman, M. F., & Pashos, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.6908 · Cited by 365 · see citing works
Long‐term effects of androgen deprivation therapy in prostate cancer patients
Basaria, S. S., Lieb, J., Tang, A., DeWeese, T. L., Carducci, M. A., Eisenberger, M. A., & Dobs, A. S. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01551.x · Cited by 359 · see citing works
Reciprocal relations of subcutaneous and visceral fat to bone structure and strength
Gilsanz, V., Chalfant, J., Mo, A. O., Lee, D. C., Dorey, F. J., & Mittelman, S. D. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2422 · Cited by 351 · see citing works
Impact of Androgen Deprivation Therapy on Cardiovascular Disease and Diabetes
Alibhai, S. M. H., Duong-Hua, M., Sutradhar, R., Fleshner, N. E., Warde, P. R., Cheung, A. M., & Paszat, L. F. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0923 · Cited by 334 · see citing works
Osteoporosis in Men
Ebeling, P. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmcp0707217 · Cited by 332 · see citing works
Randomized Controlled Trial of Annual Zoledronic Acid to Prevent Gonadotropin-Releasing Hormone Agonist–Induced Bone Loss in Men With Prostate Cancer
Michaelson, M. D., Kaufman, D. S., Lee, H., McGovern, F. J., Kantoff, P. W., Fallon, M. A., Finkelstein, J. S., & Smith, M. R. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3361 · Cited by 330 · see citing works
Review of major adverse effects of androgen‐deprivation therapy in men with prostate cancer
Taylor, L. G., Canfield, S. E., & Du, X. L. (2009) · Cancer · doi:10.1002/cncr.24283 · Cited by 325 · see citing works
Effect of Once-Weekly Oral Alendronate on Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
Greenspan, S. L., Nelson, J. B., Trump, D. L., & Resnick, N. M. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-6-200703200-00006 · Cited by 301 · see citing works
Resistance Training and Reduction of Treatment Side Effects in Prostate Cancer Patients
Galvao, D. A., Nosaka, K., Taaffe, D. R., Spry, N. A., Kristjanson, L. J., McGuigan, M. R., Suzuki, K., Yamaya, K., & Newton, R. U. (2006) · Medicine & Science in Sports & Exercise · doi:10.1249/01.mss.0000233803.48691.8b · Cited by 297 · see citing works
Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia
Dockery, F., Bulpitt, C. J., AGARWAL, S., Donaldson, M., & Rajkumar, C. (2003) · Clinical Science · doi:10.1042/cs20020209 · Cited by 294 · see citing works
Quality of life three years after diagnosis of localised prostate cancer: population based cohort study
Smith, D. P., King, M. T., Egger, S. J., Berry, M. P., Stricker, P. D., Cozzi, P. J., Ward, J., O’Connell, D. L., & Armstrong, B. K. (2009) · BMJ · doi:10.1136/bmj.b4817 · Cited by 286 · see citing works
Low Free Testosterone Predicts Frailty in Older Men: The Health in Men Study
Hyde, Z., Flicker, L., Almeida, O. P., Hankey, G. J., McCaul, K. A., Chubb, S. A. P., & Yeap, B. B. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2754 · Cited by 286 · see citing works
Osteoporosis in men with prostate carcinoma receiving androgen‐deprivation therapy
DIAMOND, T. H., Higano, C. S., Smith, M. R., Guise, T. A., & Singer, F. R. (2004) · Cancer · doi:10.1002/cncr.20056 · Cited by 255 · see citing works
Quality-of-Life Outcomes After Primary Androgen Deprivation Therapy: Results From the Prostate Cancer Outcomes Study
Potosky, A. L., Knopf, K., Clegg, L. X., Albertsen, P. C., Stanford, J. L., Hamilton, A. S., Gilliland, F. D., Eley, J. W., Stephenson, R. A., & Hoffman, R. M. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.17.3750 · Cited by 251 · see citing works
Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK Expert Group
Reid, D. M., Doughty, J., Eastell, R., Heys, S. D., Howell, A., McCloskey, E. V., Powles, T. J., Selby, P. L., & Coleman, R. E. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.03.007 · Cited by 229 · see citing works
Cognitive effects of hormone therapy in men with prostate cancer
Nelson, C. J., Lee, J. S., Gamboa, M. C., & Roth, A. J. L. (2008) · Cancer · doi:10.1002/cncr.23658 · Cited by 218 · see citing works
Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade
STRUM, S. B., McDERMED, J. E., SCHOLZ, M. C., JOHNSON, H., & TISMAN, G. (1997) · British Journal of Urology · doi:10.1046/j.1464-410x.1997.00234.x · Cited by 215 · see citing works
Risk of Clinical Fractures After Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer
Smith, M. R., Boyce, S. P., Moyneur, É., Duh, M. S., Raut, M. K., & Brandman, J. (2005) · The Journal of Urology · doi:10.1016/s0022-5347(05)00033-9 · Cited by 213 · see citing works
Impaired skeletal muscle development and function in male, but not female, genomic <i>androgen receptor</i> knockout mice
MacLean, H. E., Chiu, W. S. M., Notini, A. J., Axell, A.-M., Davey, R. A., McManus, J. F., Ma, C., Plant, D. R., Lynch, G. S., & Zajac, J. D. (2008) · The FASEB Journal · doi:10.1096/fj.08-105726 · Cited by 209 · see citing works
Self-citation
SKELETAL FRACTURE ASSOCIATED WITH ANDROGEN SUPPRESSION INDUCED OSTEOPOROSIS: THE CLINICAL INCIDENCE AND RISK FACTORS FOR PATIENTS WITH PROSTATE CANCER
Oefelein, M. G., RICCHUITI, V., Conrad, W. G., Seftel, A. D., Bodner, D. R., Goldman, H. B., & Resnick, M. (2001) · The Journal of Urology · doi:10.1016/s0022-5347(05)65661-3 · Cited by 188 · see citing works
Prevalence of Osteoporosis During Long-Term Androgen Deprivation Therapy in Patients with Prostate Cancer
Moróte, J., Planas, J., Anna Orsola, A., Junquera, J. M. A., Salvador, C., Trilla, E., Raventos, C. X., Cecchini, L., Encabo, G., & Reventós, J. (2007) · Urology · doi:10.1016/j.urology.2006.11.002 · Cited by 185 · see citing works
Androgen Deprivation Therapy in Prostate Cancer and Metabolic Risk for Atherosclerosis
Shahani, S., Braga‐Basaria, M., & Basaria, S. S. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2595 · Cited by 183 · see citing works
Update in Male Osteoporosis
Khosla, S. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1740 · Cited by 174 · see citing works
Risk of the "Androgen Deprivation Syndrome" in Men Receiving Androgen Deprivation for Prostate Cancer
Shahinian, V. B., Kuo, Y., Freeman, J. L., & Goodwin, J. S. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.4.465 · Cited by 162 · see citing works
Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
Smith, M. R., Morton, R. A., Barnette, K. G., SIEBER, P. R., Malkowicz, S. B., Rodriguez, D., Hancock, M. L., & Steiner, M. S. (2012) · The Journal of Urology · doi:10.1016/j.juro.2012.11.016 · Cited by 160 · see citing works
The effect of androgen deprivation therapy on body composition in men with prostate cancer: Systematic review and meta-analysis
Haseen, F., Murray, L., Cardwell, C. R., O’Sullivan, J. M., & Cantwell, M. M. (2010) · Journal of Cancer Survivorship · doi:10.1007/s11764-009-0114-1 · Cited by 159 · see citing works
Androgen deprivation therapy for prostate cancer: new concepts and concerns
Smith, M. R. (2007) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32814db88c · Cited by 157 · see citing works
Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial
Irani, J., Salomon, L., Oba, R., Bouchard, P., & Mottet, N. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70338-9 · Cited by 149 · see citing works
PILOT EVALUATION OF VENLAFAXINE FOR THE TREATMENT OF HOT FLASHES IN MEN UNDERGOING ANDROGEN ABLATION THERAPY FOR PROSTATE CANCER
Quella, S. K., Loprinzi, C. L., Sloan, J. A., Novotny, P. J., Perez, E. A., Burch, P. A., Antolak, S. J., & Pisansky, T. M. (1999) · The Journal of Urology · doi:10.1097/00005392-199907000-00024 · Cited by 146 · see citing works
Evaluation of Tamoxifen and Anastrozole in the Prevention of Gynecomastia and Breast Pain Induced by Bicalutamide Monotherapy of Prostate Cancer
Boccardo, F., Rubagotti, A., Battaglia, M., Di Tonno, P., Selvaggi, F. P., Conti, G., Comeri, G., Bertaccini, A., Martorana, G., Galassi, P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.013 · Cited by 145 · see citing works
Prediabetes: a position statement from the Australian Diabetes Society and Australian Diabetes Educators Association
Twigg, S. M., Kamp, M. C., Davis, T. M. E., Neylon, E. K., & Flack, J. R. (2007) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2007.tb00998.x · Cited by 133 · see citing works
Age‐related changes in testosterone and the role of replacement therapy in older men
Allan, C. A., & McLachlan, R. I. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02002.x · Cited by 128 · see citing works
Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
Smith, M. R., Morton, R. A., Barnette, K. G., SIEBER, P. R., Malkowicz, S. B., Rodriguez, D., Hancock, M. L., & Steiner, M. S. (2010) · The Journal of Urology · doi:10.1016/j.juro.2010.06.022 · Cited by 121 · see citing works
Mineralization and Bone Resorption Are Regulated by the Androgen Receptor in Male Mice
Chiang, C. Y., Chiu, M. W. S., Moore, A., Anderson, P., Ghasemzadeh, A., McManus, J. F., Ma, C., Seeman, E., Clemens, T. L., Morris, H. A., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081217 · Cited by 119 · see citing works
Self-citation
Toremifene Increases Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: Interim Analysis of a Multicenter Phase 3 Clinical Study
Smith, M. R., Malkowicz, S. B., Chu, F. M., Forrest, J. B., Price, D., SIEBER, P. R., Barnette, K. G., Rodriguez, D., & Steiner, M. S. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.08.137 · Cited by 117 · see citing works
Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?
Higano, C. S. (2008) · Nature Clinical Practice Urology · doi:10.1038/ncpuro0995 · Cited by 109 · see citing works
Testosterone and type 2 diabetes
Grossmann, M., Gianatti, E. J., & Zajac, J. D. (2010) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32833919cf · Cited by 108 · see citing works
Self-citation
Bone and metabolic health in patients with non‐metastatic prostate cancer who are receiving androgen deprivation therapy
Grossmann, M., Hamilton, E. J., Gilfillan, C. P., Bolton, D. M., Joon, D. L., & Zajac, J. D. (2011) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2011.tb02979.x · Cited by 105 · see citing works
Self-citation
Fracture Types and Risk Factors in Men With Prostate Cancer on Androgen Deprivation Therapy: A Matched Cohort Study of 19,079 Men
Alibhai, S. M. H., Duong-Hua, M., Cheung, A. M., Sutradhar, R., Warde, P. R., Fleshner, N. E., & Paszat, L. F. (2010) · The Journal of Urology · doi:10.1016/j.juro.2010.04.068 · Cited by 105 · see citing works
CHANGING PATTERNS IN COMPETING CAUSES OF DEATH IN MEN WITH PROSTATE CANCER: A POPULATION BASED STUDY
Lu‐Yao, G. L., Stukel, T. A., & Yao, S. (2004) · The Journal of Urology · doi:10.1097/01.ju.0000127740.96006.1a · Cited by 105 · see citing works
Structural Decay of Bone Microarchitecture in Men with Prostate Cancer Treated with Androgen Deprivation Therapy
Hamilton, E. J., Ghasemzadeh, A., Gianatti, E., Joon, D. L., Bolton, D. M., Zebaze, R. M. D., Seeman, E., Zajac, J. D., & Grossmann, M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0902 · Cited by 105 · see citing works
Self-citation
Effects of the Luteinizing Hormone-Releasing Hormone Agonist Leuprolide on Lipoproteins, Fibrinogen and Plasminogen Activator Inhibitor in Patients with Benign Prostatic Hyperplasia
Eri, L. M., Urdal, P., & Bechensteen, A. G. (1995) · The Journal of Urology · doi:10.1016/s0022-5347(01)67239-2 · Cited by 100 · see citing works
Androgen deprivation and cognition in prostate cancer
Salminen, E. K., Portin, R. I., Korpela, J., Bäckman, H., Parvinen, L.-M., Helenius, H. Y. M., & Nurmi, M. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601235 · Cited by 100 · see citing works
Metabolic sequelae associated with androgen deprivation therapy for prostate cancer
Faris, J. E., & Smith, M. R. (2010) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283391fd1 · Cited by 99 · see citing works
Bone Mineral Density Changes in Patients With Prostate Cancer During the First 2 Years of Androgen Suppression
Moróte, J., Anna Orsola, A., Junquera, J. M. A., Planas, J., Trilla, E., Raventos, C. X., Cecchini, L., Encabo, G., & Reventós, J. (2006) · The Journal of Urology · doi:10.1016/s0022-5347(05)00999-7 · Cited by 94 · see citing works
The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer
Lubeck, D. P., Grossfeld, G. D., & Carroll, P. R. (2001) · Urology · doi:10.1016/s0090-4295(01)01250-x · Cited by 91 · see citing works
Ten-Year Survival in Patients with Metastatic Prostate Cancer
Tangen, C. M., Faulkner, J. R., Crawford, E. D., Thompson, I. M., Hirano, D., Eisenberger, M. A., & Hussain, M. (2003) · Clinical Prostate Cancer · doi:10.3816/cgc.2003.n.011 · Cited by 85 · see citing works
Fracture risk in Danish men with prostate cancer: a nationwide register study
Abrahamsen, B., Nielsen, M. F., Eskildsen, P. C., Andersen, J. T., Walter, S., & Brixen, K. (2007) · British Journal of Urology · doi:10.1111/j.1464-410x.2007.07163.x · Cited by 77 · see citing works
Pilot Evaluation of Paroxetine for Treating Hot Flashes in Men
Loprinzi, C. L., Barton, D. L., Carpenter, L. A., Sloan, J. A., Novotny, P. J., Gettman, M. T., & Christensen, B. J. (2004) · Mayo Clinic Proceedings · doi:10.4065/79.10.1247 · Cited by 77 · see citing works
OSTEOPOROSIS AND SPINAL FRACTURES IN MEN WITH PROSTATE CANCER: RISK FACTORS AND EFFECTS OF ANDROGEN DEPRIVATION THERAPY
DIAMOND, T. H., Bucci, J. A., Kersley, J. H., Aslan, P., LYNCH, W. B., & Bryant, C. (2004) · The Journal of Urology · doi:10.1097/01.ju.0000130508.61020.66 · Cited by 69 · see citing works
Approach to the Prostate Cancer Patient with Bone Disease
Greenspan, S. L. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1402 · Cited by 67 · see citing works
Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy [An erratum to this Article has been published in Cancer 2006;106(11):2530]
Tanvetyanon, T. (2004) · Cancer · doi:10.1002/cncr.20766 · Cited by 63 · see citing works
Cost-Effectiveness of Fracture Prevention in Men Who Receive Androgen Deprivation Therapy for Localized Prostate Cancer
Ito, K., Elkin, E. B., Girotra, M., & Morris, M. J. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-10-201005180-00002 · Cited by 60 · see citing works
Suppression of bone density loss and bone turnover in patients with hormone‐sensitive prostate cancer and receiving zoledronic acid
Ryan, C. W., Huo, D., Bylow, K. A., Demers, L. M., Stadler, W. M., Henderson, T. O., & Vogelzang, N. J. (2007) · British Journal of Urology · doi:10.1111/j.1464-410x.2007.06853.x · Cited by 60 · see citing works
The Role of Primary Androgen Deprivation Therapy in Localized Prostate Cancer
Wong, Y., Freedland, S. J., Egleston, B. L., Vapiwala, N., Uzzo, R. G., & Armstrong, K. (2009) · European Urology · doi:10.1016/j.eururo.2009.03.066 · Cited by 57 · see citing works
Single infusion of zoledronic acid to prevent androgen deprivation therapy‐induced bone loss in men with hormone‐naive prostate carcinoma
Satoh, T., Kimura, M., Matsumoto, K., Tabata, K., Okusa, H., Bessho, H., Iwamura, M., Ishiyama, H., Hayakawa, K., & Baba, S. (2009) · Cancer · doi:10.1002/cncr.24404 · Cited by 48 · see citing works
11: Androgen deficiency and replacement therapy in men
Handelsman, D. J., & Zajac, J. D. (2004) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2004.tb06060.x · Cited by 47 · see citing works
Self-citation
Analysis of the Impact of Androgen Deprivation Therapy on Sildenafil Citrate Response Following Radiation Therapy for Prostate Cancer
Telöken, P., Ohebshalom, M., Mohideen, N., & Mulhall, J. P. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.08.007 · Cited by 47 · see citing works
DNA-binding-dependent androgen receptor signaling contributes to gender differences and has physiological actions in males and females
MacLean, H. E., Moore, A., Sastra, S. A., Morris, H. A., Ghasemzadeh, A., Rana, K., Axell, A.-M., Notini, A. J., Handelsman, D. J., Seeman, E., et al. (2010) · Journal of Endocrinology · doi:10.1677/joe-10-0026 · Cited by 45 · see citing works
Self-citation
Management of decreased bone mineral density in men starting androgen‐deprivation therapy for prostate cancer
Panju, A. H., Breunis, H., Cheung, A. M., Leach, M., Fleshner, N. E., Warde, P. R., Duff-Canning, S. J., Krahn, M. D., Naglie, G., Tannock, I. F., et al. (2009) · British Journal of Urology · doi:10.1111/j.1464-410x.2008.08156.x · Cited by 42 · see citing works
Alendronate decreases the fracture risk in patients with prostate cancer on androgen‐deprivation therapy and with severe osteopenia or osteoporosis
Planas, J., Trilla, E., Raventos, C. X., Cecchini, L., Anna Orsola, A., Salvador, C., Placer, J., Encabo, G., & Moróte, J. (2009) · British Journal of Urology · doi:10.1111/j.1464-410x.2009.08622.x · Cited by 38 · see citing works
Preventive effect of risedronate on bone loss in men receiving androgen‐deprivation therapy for prostate cancer
Ishizaka, K., Machida, T., Kobayashi, S., Kanbe, N., Kitahara, S., & Yoshida, K. (2007) · International Journal of Urology · doi:10.1111/j.1442-2042.2007.01911.x · Cited by 37 · see citing works
Maintaining bone health in patients with prostate cancer
Holmes-Walker, D. J., Woo, H. H., Gurney, H., Do, V. T., & Chipps, D. R. (2006) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2006.tb00180.x · Cited by 32 · see citing works
Risedronate Recovers Bone Loss in Patients With Prostate Cancer Undergoing Androgen-deprivation Therapy
Izumi, K., Mizokami, A., Sugimoto, K., Narimoto, K., Miwa, S., Maeda, Y., Kadono, Y., Takashima, M., Koh, E., & Namiki, M. (2009) · Urology · doi:10.1016/j.urology.2009.01.046 · Cited by 31 · see citing works
Risk of Clinical Fractures After Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer
Smith, M. R., Boyce, S. P., Moyneur, É., Duh, M. S., Raut, M. K., & Brandman, J. (2006) · The Journal of Urology · doi:10.1097/00005392-200601000-00035 · Cited by 25 · see citing works
Urinary calcium excretion in the monitoring of bone metastases from prostatic carcinoma
Francini, G., Petrioli, R., Gonnelli, S., Correale, P., Pozzessere, D., Marsili, S., Montagnani, A., Lucani, B., Rossi, S., Monaco, R. D., et al. (2001) · Cancer · doi:10.1002/1097-0142(20010915)92:6 · Cited by 15 · see citing works
1BA Increased cardiovascular morbidity and mortality following endocrine treatment for prostate cancer: an analysis in 30,642 men in PCBaSe Sweden
Hemelrijck, M. V., Garmo, H., Bratt, O., Bill‐Axelson, A., Lambe, M. P., Stattin, P., Holmberg, L., & Adolfsson, J. (2009) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(09)72024-5 · Cited by 2 · see citing works
Untitled work
(1998) · doi:10.1002/(sici)1097-0142(19980915)83:6

Flagged first, then by citations

4 of the 102 references couldn’t be matched to a known paper.

Sorted by citations

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586 · see citing works
Androgen Receptor Structure, Function and Biology: From Bench to Bedside.
(2016) · Europe PMC (PubMed Central) · Cited by 623 · see citing works
Self-citation
American Cancer Society prostate cancer survivorship care guidelines
Skolarus, T. A., Wolf, A. M. D., Erb, N. L., Brooks, D. D., Rivers, B. M., Underwood, W., Salner, A., Zeléfsky, M. J., Aragon‐Ching, J. B., Slovin, S. F., et al. (2014) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21234 · Cited by 398 · see citing works
Lowered testosterone in male obesity: Mechanisms, morbidity and management
Grossmann, M., Tang Fui, M., & Dupuis, P. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.122365 · Cited by 293 · see citing works
Self-citation
A Perspective on Middle-Aged and Older Men With Functional Hypogonadism: Focus on Holistic Management
Grossmann, M., & Matsumoto, A. M. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3580 · Cited by 246 · see citing works
Self-citation
Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review
Gardner, J. R., Livingston, P. M., & Fraser, S. F. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.5523 · Cited by 243 · see citing works
Psychological effects of androgen‐deprivation therapy on men with prostate cancer and their partners
Donovan, K. A., Walker, L. M., Wassersug, R. J., Thompson, L. M. A., & Robinson, J. W. (2015) · Cancer · doi:10.1002/cncr.29672 · Cited by 136 · see citing works
A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer
Westaby, D., de la Maza, M. D. F., Paschalis, A., Jiménez‐Vacas, J. M., Welti, J. C., Bono, J. S. D., & Sharp, A. (2021) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-052220-015912 · Cited by 131 · see citing works
Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer
Gardner, T. A., Elzey, B. D., & Hahn, N. M. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.19795 · Cited by 124 · see citing works
Androgens Induce Invasiveness of Triple Negative Breast Cancer Cells Through AR/Src/PI3-K Complex Assembly
Giovannelli, P., Donato, M. D., Auricchio, F., Castoria, G., & Migliaccio, A. (2019) · Scientific Reports · doi:10.1038/s41598-019-41016-4 · Cited by 109 · see citing works
Current therapeutic options in metastatic castration-resistant prostate cancer
Ingrosso, G., Detti, B., Scartoni, D., Lancia, A., Giacomelli, I., Baki, M., Carta, G. A., Livi, L., & Santoni, R. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.10.001 · Cited by 101 · see citing works
Testosterone and glucose metabolism in men: current concepts and controversies.
Grossmann, M. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0393 · Cited by 96 · see citing works
Self-citation
Androgens and prostate cancer; pathogenesis and deprivation therapy
Grossmann, M., Cheung, A. S., & Zajac, J. D. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.05.001 · Cited by 89 · see citing works
Self-citation
Human androgen deficiency: insights gained from androgen receptor knockout mouse models
Zajac, J. D., Rana, K., & Davey, R. A. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.122590 · Cited by 84 · see citing works
Self-citation
Luteinizing Hormone–Releasing Hormone Agonists: A Quick Reference for Prevalence Rates of Potential Adverse Effects
Walker, L. M., Tran, S., & Robinson, J. W. (2013) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2013.05.004 · Cited by 81 · see citing works
Androgens, diabetes and prostate cancer
Grossmann, M., & Wittert, G. (2012) · Endocrine Related Cancer · doi:10.1530/erc-12-0067 · Cited by 77 · see citing works
Self-citation
Hematological changes during androgen deprivation therapy
Grossmann, M., & Zajac, J. D. (2012) · Asian Journal of Andrology · doi:10.1038/aja.2011.102 · Cited by 62 · see citing works
Self-citation
The complex association between metabolic syndrome and male hypogonadism
Dimopoulou, C., Goulis, D. G., Corona, G., & Maggi, M. (2018) · Metabolism · doi:10.1016/j.metabol.2018.03.024 · Cited by 62 · see citing works
Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non‐metastatic prostate cancer: implementation of standardized management guidelines
Cheung, A. S., Pattison, D. A., Bretherton, I., Hoermann, R., Joon, D. L., Ho, E., Jenkins, T., Hamilton, E. J., Bate, K. L., Chan, I., et al. (2013) · Andrology · doi:10.1111/j.2047-2927.2013.00093.x · Cited by 56 · see citing works
Self-citation
Patients and partners lack knowledge of androgen deprivation therapy side effects
Walker, L. M., Tran, S., Wassersug, R. J., Thomas, B. C., & Robinson, J. W. (2012) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2011.12.015 · Cited by 50 · see citing works
Characteristics and predictors of fatigue among men receiving androgen deprivation therapy for prostate cancer: a controlled comparison
Nelson, A. M., Gonzalez, B. D., Jim, H., Cessna, J. M., Sutton, S. K., Small, B. J., Fishman, M., Zachariah, B., & Jacobsen, P. B. (2016) · Supportive Care in Cancer · doi:10.1007/s00520-016-3241-z · Cited by 48 · see citing works
Effect of androgen deprivation therapy on sexual function and bother in men with prostate cancer: a controlled comparison
Donovan, K. A., Gonzalez, B. D., Nelson, A. M., Fishman, M. N., Zachariah, B., & Jacobsen, P. B. (2018) · Psycho-Oncology · doi:10.1002/pon.4463 · Cited by 46 · see citing works
Bone Health Following Bariatric Surgery: An Update
Saad, R. K., Habli, D., Sabbagh, R. E., & Chakhtoura, M. (2019) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2019.08.002 · Cited by 42 · see citing works
Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review
Zhou, T. T., Sun, Y.-H., Zhang, W., Wu, T., Chen, Q., Shi, X., Xiao, G., Zhao, L., & Xu, C. (2016) · Asian Journal of Andrology · doi:10.4103/1008-682x.178483 · Cited by 40 · see citing works
Metabolic effects of androgen deprivation therapy
Choi, S. M., & Kam, S. C. (2015) · Korean journal of urology · doi:10.4111/kju.2015.56.1.12 · Cited by 36 · see citing works
Improving the management of patients with prostate cancer receiving long‐term androgen deprivation therapy
Schulman, C., Irani, J., & Aapro, M. (2012) · British Journal of Urology · doi:10.1111/j.1464-410x.2012.11216.x · Cited by 33 · see citing works
Obesity and age as dominant correlates of low testosterone in men irrespective of diabetes status
Fui, M. N. T., Hoermann, R., Cheung, A. S., Gianatti, E., Zajac, J. D., & Grossmann, M. (2013) · Andrology · doi:10.1111/j.2047-2927.2013.00124.x · Cited by 33 · see citing works
Self-citation
The role of exercise in the management of adverse effects of androgen deprivation therapy for prostate cancer: a rapid review
Edmunds, K., Tuffaha, H., Scuffham, P., Galvao, D. A., & Newton, R. U. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-020-05637-0 · Cited by 34 · see citing works
Etiology and Management of Dyslipidemia in Patients With Cancer
de Jesus, M., Mohammed, T. J., Singh, M., Tiu, J. G., & Kim, A. S. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.892335 · Cited by 32 · see citing works
A systematic review of physical activity-based behaviour change interventions reaching men with prostate cancer
Finlay, A., Wittert, G., & Short, C. E. (2018) · Journal of Cancer Survivorship · doi:10.1007/s11764-018-0694-8 · Cited by 30 · see citing works
The Use of Dietary Supplements to Alleviate Androgen Deprivation Therapy Side Effects during Prostate Cancer Treatment
Dueregger, A., Heidegger, I. M., Ofer, P., Perktold, B., Ramoner, R. E., Klocker, H., & Eder, I. E. (2014) · Nutrients · doi:10.3390/nu6104491 · Cited by 28 · see citing works
Estradiol for the mitigation of adverse effects of androgen deprivation therapy
Russell, N., Cheung, A. S., & Grossmann, M. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0153 · Cited by 23 · see citing works
Self-citation
TGFβ Superfamily Members Mediate Androgen Deprivation Therapy-Induced Obese Frailty in Male Mice
Pan, C., Singh, S. T., Sahasrabudhe, D. M., Chakkalakal, J. V., Krolewski, J. J., & Nastiuk, K. L. (2016) · Endocrinology · doi:10.1210/en.2016-1580 · Cited by 22 · see citing works
Risk of dementia following androgen deprivation therapy for treatment of prostate cancer
Krasnova, A., Epstein, M. R., Marchese, M., Dickerman, B. A., Cole, A. P., Lipsitz, S. R., Nguyen, P. L., Kibel, A. S., Choueiri, T. K., Basaria, S. S., et al. (2019) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-019-0189-3 · Cited by 21 · see citing works
FSH Suppression Does Not Affect Bone Turnover in Eugonadal Men
Uihlein, A. V., Finkelstein, J. S., Lee, H., & Leder, B. Z. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3246 · Cited by 19 · see citing works
Prostate tumor–derived GDF11 accelerates androgen deprivation therapy–induced sarcopenia
Pan, C., Jaiswal, N., Zulia, Y., Singh, S. T., Sha, K., Mohler, J. L., Eng, K. H., Chakkalakal, J. V., Krolewski, J. J., & Nastiuk, K. L. (2020) · JCI Insight · doi:10.1172/jci.insight.127018 · Cited by 18 · see citing works
The lived experience of physically active older prostate cancer survivors on androgen deprivation therapy
Clair, V. W., Malcolm, W., & Keogh, J. (2013) · The Aging Male · doi:10.3109/13685538.2013.818113 · Cited by 18 · see citing works
Castration induces satellite cell activation that contributes to skeletal muscle maintenance
Klose, A. M., Liu, W., Paris, N. D., Forman, S., Krolewski, J. J., Nastiuk, K. L., & Chakkalakal, J. V. (2018) · JCSM Rapid Communications · doi:10.1002/j.2617-1619.2018.tb00004.x · Cited by 15 · see citing works
The epigenetic function of androgen receptor in prostate cancer progression
Sawada, T., Kanemoto, Y., Kurokawa, T., & Kato, S. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1083486 · Cited by 15 · see citing works
A Novel Liver-targeted Testosterone Therapy for Sarcopenia in Androgen Deprived Men With Prostate Cancer
Rhee, H., Navaratnam, A. K., Олейникова, И. Н., Gilroy, D., Scuderi, Y., Heathcote, P. S., Nguyen, T. V., Wood, S., & Ho, K. K. Y. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab116 · Cited by 13 · see citing works
Practice Patterns Compared with Evidence-based Strategies for the Management of Androgen Deprivation Therapy–Induced Side Effects in Prostate Cancer Patients: Results of a European Web-based Survey
Bultijnck, R., Surcel, C. I., Ploussard, G., Briganti, A., Visschere, P. D., Fütterer, J. J., Ghadjar, P., Giannarini, G., Hendrik Isbarn, A., Massard, C., et al. (2016) · European Urology Focus · doi:10.1016/j.euf.2016.02.009 · Cited by 13 · see citing works
Hypothalamic-Pituitary-Thyroid Axis Set Point Alterations Are Associated With Body Composition in Androgen-Deprived Men
Hoermann, R., Cheung, A. S., Milne, M., & Grossmann, M. (2017) · Journal of the Endocrine Society · doi:10.1210/js.2017-00057 · Cited by 13 · see citing works
Self-citation
Effectiveness of testosterone therapy in obese men with low testosterone levels, for losing weight, controlling obesity complications, and preventing cardiovascular events
Mangolim, A. S., Brito, L. D. A. R., & Nogueira, V. D. S. N. (2018) · Medicine · doi:10.1097/md.0000000000010482 · Cited by 12 · see citing works
Myostatin Inhibition: A New Treatment for Androgen Deprivation-Induced Sarcopenia?
Grossmann, M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3290 · Cited by 12 · see citing works
Self-citation
Influence of Baseline Cardiovascular Comorbidities on Mortality after Androgen Deprivation Therapy for Metastatic Prostate Cancer
Wu, S., Fang, S., Hwang, O., Shih, H., & Shao, Y. J. (2020) · Cancers · doi:10.3390/cancers12010189 · Cited by 11 · see citing works
Radiotherapy before or during androgen-deprivation therapy does not blunt the exercise-induced body composition protective effects in prostate cancer patients: A secondary analysis of two randomized controlled trials
Newton, R. U., Mavropalias, G., Fragala, M. S., Kraemer, W. J., Häkkinen, K., Taaffe, D. R., Spry, N. A., Joseph, D. J., & Galvao, D. A. (2021) · Experimental Gerontology · doi:10.1016/j.exger.2021.111427 · Cited by 7 · see citing works
Sexual function outcomes of radiation and androgen deprivation therapy for localized prostate cancer in men with good baseline function
Joyce, D., Wallis, C. J. D., Luckenbaugh, A. N., Huelster, H. L., Zhao, Z., Hoffman, K. E., Huang, L., Koyama, T., Conwill, R. M., Goodman, M. G., et al. (2021) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-021-00405-5 · Cited by 7 · see citing works
Cardiometabolic Complications after Androgen Deprivation Therapy in a Man with Prostate Cancer: Effects of 3 Years Intermittent Testosterone Supplementation
Aversa, A., Francomano, D., & Lenzi, A. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00017 · Cited by 7 · see citing works
COX-2 inhibitors in prostate cancer treatment—hold your horses?
Cheung, A. S., & Grossmann, M. (2012) · Asian Journal of Andrology · doi:10.1038/aja.2012.51 · Cited by 7 · see citing works
Self-citation
Dual‐energy x‐ray absorptiometry assessment of bone health in Australian men with prostate cancer commencing androgen deprivation therapy
Hamid, M., Hayden, A. J., Moujaber, T., Turner, S., Gurney, H., Grossmann, M., & Wong, P. K. K. (2023) · The Medical Journal of Australia · doi:10.5694/mja2.51835 · Cited by 6 · see citing works
Self-citation
Sexual Function in Men Undergoing Androgen Deprivation Therapy
Gryzinski, G. M., Fustok, J. N., Raheem, O. A., & Bernie, H. L. (2022) · Androgens Clinical Research and Therapeutics · doi:10.1089/andro.2022.0002 · Cited by 6 · see citing works
Biomechanical Leg Muscle Function During Stair Ambulation in Men Receiving Androgen Deprivation Therapy
Cheung, A. S., Gray, H. A., Schache, A. G., Hoermann, R., Bicknell, J., Joon, D. L., Zajac, J. D., Pandy, M. G., & Grossmann, M. (2019) · The Journals of Gerontology Series A · doi:10.1093/gerona/glz169 · Cited by 6 · see citing works
Self-citation
The Relationships between Anabolic Hormones and Body Composition in Middle-Aged and Elderly Men with Prediabetes: A Cross-Sectional Study
Rabijewski, M., Papierska, L., & Piątkiewicz, P. (2016) · Journal of Diabetes Research · doi:10.1155/2016/1747261 · Cited by 4 · see citing works
Effects of androgen deprivation therapy on metabolic markers and bioelectrical impedance analyze in prostate cancer patients
Çakıcı, M. Ç., Canbaz, B., Kazan, Ö., Efiloğlu, Ö., Şendoğan, F., Uçar, T., Turan, T., & Yıldırım, A. (2022) · Revista Internacional de Andrología · doi:10.1016/j.androl.2020.10.007 · Cited by 4 · see citing works
Androgen-deprivation therapy in men with metastatic prostate cancer: less may not necessarily be more
Fui, M. N. T., & Grossmann, M. (2013) · Asian Journal of Andrology · doi:10.1038/aja.2013.57 · Cited by 3 · see citing works
Self-citation
The effect of estradiol add-back: a longitudinal MRI study in prostate cancer patients
Dandash, O., Allebone, J., Mirabelli, A. G., Russell, N., Grossmann, M., Gogos, A., & Kanaan, R. (2024) · Endocrine Connections · doi:10.1530/ec-23-0409 · Cited by 2 · see citing works
Self-citation
Pitfalls in bone density monitoring in prostate cancer during anti-resorptive treatment
Cheung, Y.-M. M., Ramchand, S. K., & Grossmann, M. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4481-1 · Cited by 2 · see citing works
Self-citation
Cognitive function in prostate cancer patients on androgen deprivation therapy: A case-control study
Atallah, P., Kanaan, R., Russell, N., Allebone, J., & Grossmann, M. (2020) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2020.04.005 · Cited by 2 · see citing works
Self-citation
Managing erectile dysfunction after prostate cancer treatment
Stainer, V., Skews, R., & Aning, J. J. (2022) · Prescriber · doi:10.1002/psb.1960 · Cited by 2 · see citing works
Androgens and Skeletal Biology
Wiren, K. M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415853-5.00015-7 · Cited by 2 · see citing works
Androgens and Skeletal Biology: Basic Mechanisms
Wiren, K. M. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-375098-3.50016-0 · Cited by 1 · see citing works
Vitamin C alleviates surgical castration-induced dyslipidemia in male rats
Alagbonsi, A. I., Olayaki, L. A., Adamson, M., Ayodele, O., & Oyewopo, A. O. (2016) · Nigerian Journal of Cardiology · doi:10.4103/0189-7969.187706 · Cited by 1 · see citing works
Chapter 15 – Androgens and Skeletal Biology: Basic Mechanisms
Wiren, K. M. (2013) · Cited by 1 · see citing works
Powikłania terapii hormonalnej (ADT – androgen deprivation therapy) a układ ruchu u pacjentów z rakiem prostaty
Korczak, J. (2020) · Letters in Oncology Science · doi:10.21641/los.2020.17.1.156 · Cited by 1 · see citing works
The effect of medical castration on lipid levels in black South African men with prostate cancer
Minkowitz, S., Ayeni, O., Haffejee, M., & Joffe, M. (2022) · African Journal of Urology · doi:10.1186/s12301-022-00328-0 · Cited by 1 · see citing works
Editorial Comment
Rais‐Bahrami, S., & Moreira, D. M. (2012) · The Journal of Urology · doi:10.1016/j.juro.2012.08.251
Hormonale therapie
Cnossen, A., & van Muilekom, H. A. M. (2012) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-313-8871-4_9
Current World Literature
(2012) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283542fb3
Current World Literature
(2012) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0b013e3283573126

Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them
Nguyen, P. L., Alibhai, S. M. H., Basaria, S. S., D'Amico, A. V., Kantoff, P. W., Keating, N. L., Penson, D. F., Rosario, D. J., TOMBAL, B. F., & Smith, M. R. (2014) · European Urology · doi:10.1016/j.eururo.2014.07.010 · Cited by 842 · see citing works
Androgen Deprivation in Elderly Prostate Cancer Patients: Side Effects and Their Prevention
Bishr, M. O., & Fred Saad, C. (2012) · Springer eBooks · doi:10.1007/978-0-85729-999-4_6
Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?
Grossmann, M., & Zajac, J. D. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03939.x · Cited by 68 · see citing works
Self-citation
Antiandrogene Therapie des Prostatakarzinoms
Rohayem, J., & Kliesch, S. (2012) · Der Urologe · doi:10.1007/s00120-012-2808-7 · Cited by 3 · see citing works
Side effects of androgen deprivation therapy: monitoring and minimizing toxicity
Higano, C. S. (2003) · Urology · doi:10.1016/s0090-4295(02)02397-x · Cited by 239 · see citing works

Authors: Grossmann, M., & Zajac, J. D.
Affiliations: The University of Melbourne (AU)
Corresponding author: Zajac, Jeffrey D.
ORCID: Grossmann, Mathis
Zajac, Jeffrey D.
Venue: Endocrinology and Metabolism Clinics of North America
Publisher: Elsevier BV
Published: 2011-09
Volume: 40
Issue: 3
Pages: 655-671
ISSN: 0889-8529 (ISSN-L)
DOI: 10.1016/j.ecl.2011.05.004
OpenAlex: W2074971523
Cited by: 69
References: 102
Citations by year: 2024: 1 · 2023: 2 · 2022: 5 · 2021: 4 · 2020: 5 · 2019: 4 · 2018: 6 · 2017: 4 · 2016: 7 · 2015: 2 · 2014: 6 · 2013: 10 · 2012: 12
FWCI: 1.45
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Endocrinology and Metabolism Clinics of North America (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Diagnosis and Treatment
Keywords: androgen deprivation therapy, prostate cancer, adverse effects, bone loss, fracture, fat mass, insulin resistance, metabolic syndrome, diabetes mellitus, cardiovascular risk, anemia, muscle mass loss, sexual dysfunction, neuropsychological symptoms, side effect management
MeSH terms: Androgen Antagonists, Animals, Carcinoma, Cardiovascular Physiological Phenomena, Humans, Life Style, Male, Prostatic Neoplasms, Antineoplastic Agents, Hormonal, Dietary Supplements, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Management of side effects of androgen deprivation therapy

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks